Abu Dabrh, A, Asi, N, Farah, W et al. (2015). Radiotherapy vs. radiosurgery in treating patients with acromegaly: systematic review and meta-analysis. Endocr Pract 21, 943–956.
Al-Dahmani, K, Mohammad, S, Imran, F et al. (2016). Sellar masses: an epidemiological study. Can J Neurol Sci 43, 291–297.
Beck-Peccoz, P, Persani, L, Faglia, G. (1992). Glycoprotein hormone α-subunit in pituitary adenomas. Trends Endocr Metab 3, 41–45.
Beck-Peccoz, P, Lania, A, Beckers, A, Chatterjee, K & Wemeau, J-L. (2013). European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Europ Thyroid J 2, 76–82.
Bonneville, J-F. (2016). Magnetic resonance imaging of pituitary tumors. Front Horm Res 45, 97–120.
Burrell, S, Hebb, A L O, Imran, S A, Mishra, A, Mawko, G & Clarke, D B. (2017). Visualization of 90Yttrium colloid within a cystic craniopharyngioma using PET/CT/MRI fusion. Can J Neurol Sci 44, 192–193.
Carmichael, J D, Bonert, V S, Nuño, M, Ly, D & Melmed, S. (2014). Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocr Metab 99, 1825–1833.
Chanson, P & Brochier, S. (2005). Non-functioning pituitary adenomas. J Endocr Invest 28 (11 Suppl Int), 93–99.
Colao, A, Ferone, D, Marzullo, P & Lombardi, G. (2004). Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25, 102–152.
Dolecek, T A, Propp, J M, Stroup, N E & Kruchko, C. (2012). CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 14 (Suppl 5), 1–49.
Frieze, T W, Mong, D P & Koops, M K. (2002). “Hook effect” in prolactinomas: case report and review of literature. Endocr Pract 8, 296–303.
Gadelha, M R, Bronstein, M D, Brue, T et al. (2014). Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocr 2, 875–884.
Greenman, Y, Tordjman, K, Osher, E et al. (2005). Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin Endocr 63, 39–44.
Guttenberg, K B, Mayson, S E, Sawan, C et al. (2016). Prevalence of clinically silent corticotroph macroadenomas. Clin Endocr 85, 874–880.
Heck, A, Ringstad, G, Fougner, SL et al. (2012). Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocr 77, 72–78.
Hukin, J, Steinbok, P, Lafay-Cousin, L et al. (2007). Intracystic bleomycin therapy for craniopharyngioma in children: the Canadian experience. Cancer 109, 2124–2131.
Imran, S A, Fleetwood, I G, O’Connell, C M et al. (2009). Outcome of stereotactic radiotherapy for patients with uncontrolled acromegaly. Can J Neurol Sci 36, 468–474.
Imran, S A, Tiemensma, J, Kaiser, S M et al. (2016). Morphometric changes correlate with poor psychological outcomes in patients with acromegaly Eur J Endocr 174, 41–50.
Imran, S A, Yip, C E, Papneja, N et al. (2016). Analysis and natural history of pituitary incidentalomas. Europ J Endocr 175, 1–9.
Imran, S A, Shankar, J, Hebb, A L O, Croul, S E & Clarke, D B. (2017). Radiological growth patterns of prolactinomas and nonfunctioning adenomas. Can J Neurol Sci 44, 508–513.
Jacob, J J & Bevan, J S. (2014). Should all patients with acromegaly receive somatostatin analogue therapy before surgery and, if so, for how long? Clin Endocr 81, 812–817.
Katznelson, K, Laws, E R, Melmed, S et al. (2014). Acromegaly: an endocrine society clinical practice guideline. J Clin Endocr Metab 99, 3933–3951.
Kinoshita, Y, Tominaga, A, Usui, S et al. (2016). The long-term recurrence of Rathke’s cleft cysts as predicted by histology but not by surgical procedure. J Neurosurg 125, 1002–1007.
Lucas, J W & Zada, G. (2012). Imaging of the pituitary and parasellar region. Semin Neurol 32, 320–331.
Melmed, S. (2006). Acromegaly. N Engl J Med 355, 2558–2573.
Minniti, G, Clarke, E, Scaringi, C, Enrici, R M. (2016). Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas. Rep Pract Oncol Radiother 21, 370–378.
Newell-Price, J, Trainer, P, Perra, L, Wass, J, Grossman, A & Besser, M A. (1995). A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing’s syndrome. Clin Endocr 43, 545–550.
Nieman, L K, Biller, B M, Findling, J W et al. (2008). The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocr Metab 93, 1526–1540.
Papanicolaou, D A, Yanovski, J A, Cutler, G B Jr., Chrousos, G P & Nieman, L K. (1998). A single midnight serum cortisol measurement distinguishes Cushing’s syndrome from pseudo-Cushing states. J Clin Endocr Metab 83, 1163–1167.
Petersenn, S, Beckers, A, Ferone, D et al. (2015). Therapy of endocrine disease: outcomes in patients with Cushing’s disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Europ J Endocr 172, R227–R239.
Samson, S L, Hamrahian, A H & Ezzat, S. (2015). Clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia. Endocr Pract 21, 1427–1435.
Sandret, L, Maison, P, Chanson, P. (2012). Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocr Metab 96, 1327–1335
Sharma, S T, Nieman, L K & Feelders, R A. (2015). Cushing’s syndrome: epidemiology and developments in disease management. Clin Epidemiol 7, 281–293.
Tjörnstrand, A, Gunnarsson, K, Evert, M et al. (2014).The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011. Eur J Endocr 171, 519–526.
van der Lely, A J, Biller, B M, Brue, T et al. (2012). Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocr Metab 97, 1589–1597.
Vaninetti, N, Clarke, D B, Zwicker, D A et al. (2018). A comparative population-based analysis of pituitary incidentalomas vs clinically manifesting sellar masses. Endocr Connect 7, 768–776.
Verhelst, J, Abs, R, Maiter, D et al. (1999). Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocr Metab 84, 2518–2522.
Webster, J, Piscitelli, G, Polli, A, Ferrari, CI, Ismail, I & Scanlon, M F. (1994). A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. New Engl J Med 331, 904–909.
Woo, Y S, Isidori, A M, Wat, W Z et al. (2005). Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocr Metab 90, 4963–4969.
Yip, C E, Stewart, S A, Imran, F et al. (2013). The role of morning basal serum cortisol in assessment of hypothalamic pituitary-adrenal axis. Clin Invest Med 36, E216–E222.